Trial Profile

A Randomized, double-blind, placebo-controlled multicenter Phase 3 study of NVG-291 in chronic tetraplegia

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 08 Jun 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs NVG 291 (Primary)
Indications Spinal cord injuries
Focus Adverse reactions; Registrational; Therapeutic Use
Acronyms RESTORE

Most Recent Events

18 May 2026 According to NervGen Pharma media release, company has completed a successful End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA), reaching alignment on the study parameters.
14 Apr 2026 New trial record
07 Apr 2026 According to NervGen Pharma media release, the study remains on-track for initiation in mid-2026, with study initiation activities underway.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com